Fig. 3

Incremental total costs per patient* (€, 2021) of patients with vs. without AL. *In the estimation of the incremental cost of diagnosis and treatment of AL, only those resources that are modified due to the appearance of AL have been considered. In no case is it intended to capture the total cost associated with the treatment of a patient with colorectal cancer who does not have AL. Therefore, GROUPS 1, 2 and 3 reflect the incremental cost incurred by the National Health System after the onset of AL.**In GROUP 3 patients, there is a decrease in the cost generated for closure of the stoma since a percentage of patients do not have the stoma closed in the first year as a consequence of AL